suggest that the two doses of the Pfizer-BioNTech vaccine offer good protection against the highly transmissible delta variant, particularly in reducing the risk of severe illness and hospitalizations.last week that early data from the company's booster study suggests people's antibody levels jump five- to 10-fold after a third dose, compared to their second dose months earlier — evidence it believes supports the need for a booster.
"There is a normal course of business to how this works. But these aren't normal times and they've been having all sorts of extra meetings to get things reviewed quicker and get through this emergency," said John Grabenstein, a former executive director of medical affairs for vaccines at Merck and a former Department of Defense immunologist.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer, U.S. Officials to Discuss COVID-19 Vaccine BoosterPfizer and top U.S. health officials will meet today to discuss FDA authorization of a third vaccine dose that would act as a booster shot against COVID-19. With Booster shots to be approved, health officials at CDC are going to be very rich, don't bet on just 1 booster, additional boosters to come! 😉
Source: WebMD - 🏆 709. / 51 Read more »
Pfizer, U.S. health officials to discuss COVID boosters on Monday -companyCOVID-19 vaccine maker Pfizer Inc (PFE.N) will meet with federal health officials as soon as Monday to discuss the need for a booster dose of the coronavirus vaccine as it prepares to seek authorization, the company said on Sunday. For all those who are new to this working from home Bitcoin trading options Here's a little tip: Get a trusted Bitcoin expert and stick to him RonelMoses32 Invest and play at similar times each day. Because : In times of chaos, your investment is your anchor to success⚖️ If the unit price for each shot remains the same the firm will earn 50% more than it earned on a 2-shot regime. Not a bad business venture at all, go for it Pfizer, go for the tax payers jugular.
Source: Reuters - 🏆 2. / 97 Read more »